vs
Side-by-side financial comparison of Entera Bio Ltd. (ENTX) and Alaunos Therapeutics, Inc. (TCRT). Click either name above to swap in a different company.
Entera Bio Ltd. produced more free cash flow last quarter ($-1.9M vs $-3.0M).
Entera Bio Ltd. is a clinical-stage biopharmaceutical company focused on developing oral formulations of biologics and large-molecule therapies traditionally administered via injection. Its core pipeline targets treatments for rare diseases, metabolic disorders, and autoimmune conditions, serving patient populations across global markets.
Alaunos Therapeutics, Inc. is a clinical-stage biotechnology company that develops novel T cell receptor (TCR) immunotherapies for the treatment of hard-to-treat solid tumors. The firm focuses on advancing precision oncology candidates targeting shared tumor antigens, serving global oncology patient populations via internal R&D and cross-sector partnerships.
ENTX vs TCRT — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $0 | $3.0K |
| Net Profit | $-3.0M | — |
| Gross Margin | — | — |
| Operating Margin | — | — |
| Net Margin | — | — |
| Revenue YoY | — | -40.0% |
| Net Profit YoY | -27.9% | -20.5% |
| EPS (diluted) | $0.06 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $0 | $3.0K | ||
| Q3 25 | $0 | $0 | ||
| Q2 25 | $0 | $0 | ||
| Q1 25 | $42.0K | $2.0K | ||
| Q4 24 | $82.0K | $5.0K | ||
| Q3 24 | $42.0K | $0 | ||
| Q2 24 | $57.0K | $4.0K | ||
| Q1 24 | $0 | $1.0K |
| Q4 25 | $-3.0M | — | ||
| Q3 25 | $-3.2M | $-1.2M | ||
| Q2 25 | $-2.7M | $-1.1M | ||
| Q1 25 | $-2.6M | $-1.1M | ||
| Q4 24 | $-2.4M | — | ||
| Q3 24 | $-3.0M | $-1.1M | ||
| Q2 24 | $-2.1M | $-1.1M | ||
| Q1 24 | $-2.0M | $-1.7M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | 15.8% | — | ||
| Q1 24 | — | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | -6102.4% | -54600.0% | ||
| Q4 24 | -2850.0% | — | ||
| Q3 24 | -7192.9% | — | ||
| Q2 24 | -3798.2% | -29150.0% | ||
| Q1 24 | — | -174200.0% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | -6111.9% | -53650.0% | ||
| Q4 24 | -2875.6% | — | ||
| Q3 24 | -7192.9% | — | ||
| Q2 24 | -3763.2% | -28225.0% | ||
| Q1 24 | — | -168200.0% |
| Q4 25 | $0.06 | — | ||
| Q3 25 | $0.07 | $-0.55 | ||
| Q2 25 | $0.06 | $-0.63 | ||
| Q1 25 | $0.06 | $-0.67 | ||
| Q4 24 | $0.06 | — | ||
| Q3 24 | $0.08 | $-0.70 | ||
| Q2 24 | $0.06 | $-0.71 | ||
| Q1 24 | $0.05 | $-1.05 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $7.1M | $1.4M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $13.1M | $2.2M |
| Total Assets | $16.0M | $3.0M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $7.1M | $1.4M | ||
| Q3 25 | $8.6M | $1.9M | ||
| Q2 25 | $10.9M | $2.9M | ||
| Q1 25 | $12.6M | $319.0K | ||
| Q4 24 | $8.7M | $1.1M | ||
| Q3 24 | $6.9M | $1.7M | ||
| Q2 24 | $9.1M | $2.5M | ||
| Q1 24 | $9.2M | $4.1M |
| Q4 25 | $13.1M | $2.2M | ||
| Q3 25 | $15.2M | $2.8M | ||
| Q2 25 | $17.3M | $3.7M | ||
| Q1 25 | $19.4M | $1.1M | ||
| Q4 24 | $8.1M | $2.1M | ||
| Q3 24 | $6.5M | $2.7M | ||
| Q2 24 | $8.5M | $3.8M | ||
| Q1 24 | $8.9M | $4.8M |
| Q4 25 | $16.0M | $3.0M | ||
| Q3 25 | $17.4M | $3.7M | ||
| Q2 25 | $19.7M | $4.7M | ||
| Q1 25 | $21.6M | $2.1M | ||
| Q4 24 | $9.4M | $2.8M | ||
| Q3 24 | $7.7M | $3.5M | ||
| Q2 24 | $10.0M | $4.7M | ||
| Q1 24 | $10.2M | $6.0M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-1.8M | $-2.9M |
| Free Cash FlowOCF − Capex | $-1.9M | $-3.0M |
| FCF MarginFCF / Revenue | — | -98900.0% |
| Capex IntensityCapex / Revenue | — | 3266.7% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-7.5M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-1.8M | $-2.9M | ||
| Q3 25 | $-2.5M | $-844.0K | ||
| Q2 25 | $-1.6M | $-701.0K | ||
| Q1 25 | $-1.4M | $-772.0K | ||
| Q4 24 | $-1.5M | $-5.0M | ||
| Q3 24 | $-2.2M | $-781.0K | ||
| Q2 24 | $-1.3M | $-1.7M | ||
| Q1 24 | $-1.9M | $-1.9M |
| Q4 25 | $-1.9M | $-3.0M | ||
| Q3 25 | $-2.5M | — | ||
| Q2 25 | $-1.7M | — | ||
| Q1 25 | $-1.4M | — | ||
| Q4 24 | $-1.5M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | -98900.0% | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | -3361.9% | — | ||
| Q4 24 | -1792.7% | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | 3266.7% | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | 19.0% | — | ||
| Q4 24 | 3.7% | 0.0% | ||
| Q3 24 | 0.0% | — | ||
| Q2 24 | 0.0% | 0.0% | ||
| Q1 24 | — | 0.0% |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
